The National Institutes of Health has entered into an agreement with Israel-based health data platform developer MDClone to leverage the latter’s data analytics engine to support COVID-19 research initiatives.
NIH seeks to deploy MDClone’s platform to collate synthetic or indirectly obtained data while ensuring the privacy of patients, MDClone said Tuesday.
MDClone and NIH plan to utilize large volumes of data such as patient outcomes and treatments to create predictive models for forecasting disease severity.
Both entities also intend to use MDClone's longitudinal analytics tool to promote clinical best practices throughout a network of web-based academic healthcare databases to support computationally derived statistical assessments.
According to the MDClone, the initiative is meant to help accelerate data analysis to support clinical management as well as COVID-19 testing activities.
Established in 2016, MDClone is headquartered in Beer Sheba, Israel, and has offices in Canada and the U.S.